Search Results

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A.

Gritstone bio, Inc. and Genevant Sciences today announced an agreement pursuant to which Gritstone bio, Inc. will have a multi-year option for a non-exclusive license under Genevant’s LNP technology on a pathogen-by-pathogen basis to develop and commercialize self-amplifying RNA (samRNA) vaccines.

Genevant Sciences announced it has entered into a collaboration and nonexclusive license agreement with Tome Biosciences to combine its proprietary LNP technology with Tome’s programmable genomic integration technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.

Genevant Sciences today announced the use of its LNP technology in Gritstone bio’s (Nasdaq: GRTS) self-amplifying mRNA (samRNA) vaccine candidate against COVID-19 in its CORAL program.

Korro Bio and Genevant Sciences today announced that they have entered into an agreement to combine Korro’s powerful RNA editing platform with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).

A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.